Home > Insider Trading > Filing (0001553878-17-000047)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291963	E Barry Greene	C/O Alnylam Pharmaceuticals, Inc. 300 Third Street Cambridge MA 02142	President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-09-20	76,815	$31.39	165,399	No	4	M	Direct
Common Stock	Disposition	2017-09-20	76,815	$100.00	88,584	No	4	S	Direct
Common Stock	Acquisiton	2017-09-21	6,485	$7.10	95,069	No	4	M	Direct
Common Stock	Acquisiton	2017-09-21	5,359	$18.66	100,428	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Option 2013 (Right to Buy)	Acquisiton	2017-09-20	15,000	$0.00	15,000	$63.00
Common Stock	Stock Option (Right to Buy)	Disposition	2017-09-21	6,485	$0.00	6,485	$7.10
Common Stock	Stock Option (Right to Buy)	Disposition	2017-09-21	5,359	$0.00	5,359	$18.66
Common Stock	Stock Option (Right to Buy)	Disposition	2017-09-20	76,815	$0.00	76,815	$31.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000	2017-09-20	2023-12-17	No	4	A	Direct
85,915		2021-11-30	No	4	M	Direct
94,641		2022-12-20	No	4	M	Direct
0		2017-12-12	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,810	Indirect	By Managed Account

Footnotes

The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017.
The reporting person owns 2,810 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective September 20, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option was vested as to one-third of the shares.
The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.